ArticleTranslational cancer research2019

GSTM1 polymorphism in Oncotype DX assay is a potential predictive factor for taxane-based neoadjuvant chemotherapy in estrogen receptor-positive Chinese breast cancer patients.

Guochun Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.